Effect of Varenicline in smoking cessation after invasive treatment of coronary artery disease
Phase 4
- Conditions
- Smoking cessation.
- Registration Number
- IRCT20200719048133N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 600
Inclusion Criteria
Male sex = 18 years old
Current daily smoker of = 5 cigarettes per day
Having a history of revascularization procedure for CAD in Tehran Heart 9-12 months prior to the study
Able to consent to the study and to follow its instructions and procedures
Exclusion Criteria
Unstable cardiac disease
Known case of dementia disorders such as Alzheimer
Known case of chronic renal failure
Known or suspected unstable psychiatric disorders that require acute medical treatment
Only one member of a household is permitted to participate in the trial concurrently to minimize cohort-confounding effects
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Group differences in the continuous abstinence rate. Timepoint: Point prevalence abstinence at the end of 13 and 52 weeks of intervention. Method of measurement: Self-reported rating scales that is confirmed by one of the close relatives who lives with patient.
- Secondary Outcome Measures
Name Time Method